Select Language
NSP8
NSP8 Overview
| English Name | SARS-CoV-2-3C-like-proteinase | Approved Drugs | 7 |
| Drugs in Clinical Trials | 27 | Target Synonym | Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO |
| Highest Development Stage | Approved | ||
| English Name | SARS-CoV-2-3C-like-proteinase |
| Target Synonym | Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO |
| Approved Drugs | 7 |
| Drugs in Clinical Trials | 27 |
| Highest Development Stage | Approved |
NSP8 Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
SARS-CoV-2 (1)
- Tag
His Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
NS8-C5149 | SARS-CoV-2 | E. coli | SARS-CoV-2 (COVID-19) NSP8 Protein, His Tag |  |  |  Add to Cart |
Total: 1
- 1
NSP8 Background
NSP8, forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. By investigating the entire proteome of SARS-CoV-2, six proteins, including the S protein and five non-structural proteins (nsp3, 3CL-pro, and nsp8-10) were predicted to be adhesins, which are crucial to the viral adhering and host invasion. The S, nsp3, and nsp8 proteins were also predicted by Vaxign-ML to induce high protective antigenicity.
NSP8 Synonyms
NSP8,nsp8,Non-structural protein 8
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ebselen | SPI-1005; SPI-3005; PZ-51; DR-3305 | Phase 3 Clinical | Daiichi Sankyo Co Ltd, Sound Pharmaceuticals Inc | Bipolar Disorder; Cochlear Diseases; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Head and Neck Neoplasms; Hearing Loss; Hearing Loss, Noise-Induced; Lung Neoplasms; Meniere Disease; Neoplasms; Nervous System Diseases; Ototoxicity; Tinnitus | Details |
| Secutrelvir | S-892216 | Phase 3 Clinical | Shionogi & Co Ltd | Coronavirus Disease 2019 (COVID-19); Renal Insufficiency | Details |
| ibuzatrelvir | PF-07817883; PF-7817883 | Phase 3 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Mprosevir | WPV-01 | Phase 3 Clinical | Westlake University | Coronavirus Disease 2019 (COVID-19) | Details |
| QLS-1128 | QLS-1128 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| MIR-19 | MIR-19 | Phase 3 Clinical | St. Petersburg Scientific Research Institute of Vaccines and Sera | Coronavirus Disease 2019 (COVID-19) | Details |
| Bofutrelvir | FB-2001; DC-402234 | Phase 3 Clinical | Frontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
| Nirmatrelvir | PF-07321332 | Phase 3 Clinical | Pfizer As | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome | Details |
| CDI-988 | CDI988 | Phase 2 Clinical | Cocrystal Pharma Inc | Coronavirus Disease 2019 (COVID-19); Norovirus Infections | Details |
| Travatrelvir | 83-0060; TRX-01 | Phase 2 Clinical | Traws Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Deusitrelvir | SHEN-211; SHEN211 | Phase 2 Clinical | Hubei JKT BioPharma Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| HS-10517 | HS-10517; HS10517 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Zevotrelvir | EDP-235 | Phase 2 Clinical | Enanta Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Tollovir | Phase 2 Clinical | Todos Medical Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
| SNB-011 | SNB-01; SNB-011 | Phase 2 Clinical | Syneurx International (Taiwan) Corp | Coronavirus Disease 2019 (COVID-19) | Details |
| Pomotrelvir | PBI-0451 | Phase 1 Clinical | Pardes Biosciences Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| CMX-990 | CMX-990; CMX990 | Phase 1 Clinical | The Scripps Research Institute Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| WPV-02 | WPV-02; WPV02 | Phase 1 Clinical | Westlake Pharmaceuticals (Hangzhou) Co Ltd | Virus Diseases | Details |
| ISM-3312 | ISM-3312 | Phase 1 Clinical | Insilico Medicine Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Limnetrelvir | ABBV-903 | Phase 1 Clinical | Abbvie Inc | Details | |
| SAL-0133 | SAL-0133 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| SYH-2055 | SYH-2055 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Atilotrelvir | GST-HG171 | Phase 1 Clinical | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| ALG-097558 | ALG-097558 | Phase 1 Clinical | Aligos Therapeutics Inc, Centre for Drug Design and Discovery, Rega Institute for Medical Research | Coronavirus Disease 2019 (COVID-19) | Details |
| ASC11 | ASC-11 | Phase 1 Clinical | Ascletis Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Lufotrelvir | PF-07304814 | Phase 1 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Virus Diseases | Details |
| GS221 | GS-221; GS221 | Clinical | Grand Pharmaceutical （China） Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Olgotrelvir | STI-1558; STI1558 | Approved | Texas A&M University | Ovydso, 奥维宁 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Zhejiang Acea Pharmaceutical Co Ltd | 2025-10-28 | Coronavirus Disease 2019 (COVID-19); Pulmonary Disease, Chronic Obstructive | Details |
| Atilotrelvir/Ritonavir | Approved | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 泰中定 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 2023-11-23 | Coronavirus Disease 2019 (COVID-19) | Details | |
| Simnotrelvir | SIM-0417; SSD-8432; VV-934 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19) | Details | |
| Leritrelvir | RAY003; RAY-003; RAY-1216 | Approved | Guangdong Raynovent Biotech Co Ltd | 乐睿灵 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Guangdong Raynovent Biotech Co Ltd | 2023-03-23 | Acute Kidney Injury; Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency | Details |
| Simnotrelvir/Ritonavir | SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir | Approved | Jiangsu Simcere Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Wuhan Institute Of Virology, Chinese Academy Of Sciences | 先诺欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Renal Insufficiency | Details |
| Ensitrelvir Fumaric Acid | S-217622 | Approved | Hokkaido University, Shionogi & Co Ltd | Xocova | Japan | Coronavirus Disease 2019 (COVID-19) | Shionogi & Co Ltd | 2022-11-22 | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome; Renal Insufficiency | Details |
| Nirmatrelvir/Ritonavir | Approved | Pfizer Inc | Paxlovid, 瑞派乐 | EU | Coronavirus Disease 2019 (COVID-19) | Pfizer Europe Ma Eeig | 2022-01-28 | Coronavirus Disease 2019 (COVID-19); Immunologic Deficiency Syndromes; Post-Acute COVID-19 Syndrome; Postural Orthostatic Tachycardia Syndrome | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland